¼¼°èÀÇ À¯ÀüüÇпë ÀΰøÁö´É ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)
Global Artificial Intelligence in Genomics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
À¯ÀüüÇпë ÀΰøÁö´É ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â Á¶»ç ±â°£ÀÎ 2023-2030³â CAGR 33.3%·Î, 2022³â 11¾ï 3,000¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â ¾à 112¾ï 2,000¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
À¯ÀüüÇпë ÀΰøÁö´ÉÀº À¯ÀüÀÚ ÁúȯÀ» Áø´ÜÇϰí ÀÌÇØÇϱâ À§ÇØ ÀÇ·á ºÐ¾ß¿¡¼ ¸Ó½Å·¯´×À» Ȱ¿ëÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. À¯ÀüüÇпë ÀΰøÁö´ÉÀº ÀÇ·á Àü¹®°¡°¡ ȯÀÚÀÇ ¾ÏÀ̳ª Èñ±Í ÅðÇ༺ Áúȯ°ú °°Àº Ä¡¸íÀûÀÎ Áúº´À» ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀΰøÁö´ÉÀº À¯Àüü µ¥ÀÌÅ͸¦ ±¸Á¶ÈÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, Àΰ£ÀÌ °³ÀÔÇÏ´Â °Íº¸´Ù ´õ »¡¸® Áúº´À» ÇØ¼®ÇÏ´Â µ¥ Å« µµ¿òÀÌ µË´Ï´Ù. ÀΰøÁö´ÉÀº À¯Àü¹°ÁúÀÇ ±¸Á¶, ±â´É, ¹ß´ÞÀ» ´õ ºü¸£°Ô ºÐ¼®ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.
½ÃÀå ¿ªÇÐ :
À¯ÀüüÇпë ÀΰøÁö´É ½ÃÀåÀº ¿¹Ãø ±â°£ Áß ¸¸Á·½º·¯¿î ¼ºÀå·üÀ» º¸ÀÏ °ÍÀÔ´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡¼ À¯ÀüüÇÐÀÇ ¿ªÇÒÀº ÀΰøÁö´ÉÀÇ Àû¿ëÀÌ ÀǾàǰÀÇ ½Å¼ÓÇÑ Á¦Á¶¿¡ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀÔ´Ï´Ù. ÀǾàǰ °³¹ß ½Ã°£ ¹× ºñ¿ë Àý°¨ÀÇ Çʿ伺°ú °ø°ø ¹× ¹Î°£ ±â°üÀÇ À¯ÀüüÇпë ÀΰøÁö´É¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àΰ£ Áúº´¿¡¼ À¯Àü, »ýȰ½À°ü ¹× ȯ°æÀÇ ¿ªÇÒ¿¡ ÃÊÁ¡À» ¸ÂÃá Á¤¹ÐÀÇ·á Á¦Á¶°¡ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, ¾à¹°À» ó¹æÇϱâ Àü¿¡ ȯÀÚÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» »ç¿ëÇÏ¿© °³º° ȯÀÚÀÇ ¿ä±¸ »çÇ×À» ¹ß°ßÇÏ´Â °³ÀÎÈµÈ ÀÇ·á ¹æ¹ýÀº À¯ÀüüÇп¡¼ ÀΰøÁö´É ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
Á¶»ç º¸°í¼´Â Portre's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº À¯ÀüüÇп¡¼ ÀΰøÁö´É ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯ÀüüÇпë ÀΰøÁö´É »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
Áö¿ªº° ºÐ¼® :
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ À¯ÀüüÇп¡¼ ÀΰøÁö´É ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ¸®¼Ä¡ÆÀÀÌ °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå ÁÖ¿ä ¿ä¾à
½ÃÀå ÇÏÀ̶óÀÌÆ®
¼¼°è ½ÃÀå ½º³À¼ô
Á¦3Àå À¯ÀüüÇпë ÀΰøÁö´É - »ê¾÷ ºÐ¼®
¼·Ð : ½ÃÀå ¿ªÇÐ
½ÃÀå ÃËÁø¿äÀÎ
½ÃÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ±âȸ
»ê¾÷ µ¿Çâ
Porter's Five Forces ºÐ¼®
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®
¹ë·ùüÀÎ ºÐ¼®
¿øÀç·á ºÐ¼®
¿øÀç·á ¸®½ºÆ®
¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
¸¶ÄÉÆÃ Ã¤³Î
´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ
5 COVID-19 ¹ß»ýÀÇ ¿µÇ⠺м®
COVID-19 ¹ß»ýÀÇ ¿µÇ⠺м®
»ý»ê¿¡ ´ëÇÑ Á÷Á¢Àû ¿µÇâ
°ø±Þ¸Á°ú ½ÃÀå È¥¶õ
±â¾÷ ¹× ±ÝÀ¶ ½ÃÀå¿¡ ´ëÇÑ À繫Àû ¿µÇâ
COVID-19ÀÇ »ý»ê, ¼öÀÔ, ¼öÃâ, ¼ö¿ä¿¡ ÀÇÇÑ ¿µÇ⠺м®
½ÃÀå COVID-19 ÀÌÀü/ÀÌÈÄ
Äڷγª¹ÙÀÌ·¯½º(COVID-19) À¯ÇàÀÇ ¿µÇâ ¿¹Ãø
COVID-19 : ¹Ì½ÃÀû ¹× °Å½ÃÀû ¿äÀÎ ºÐ¼®
Á¦6Àå À¯ÀüüÇпë ÀΰøÁö´É ¼¼°è ½ÃÀå ºÐ¼® : ¿ÀÆÛ¸µº°
¿ÀÆÛ¸µº° °³¿ä
½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
¿ÀÆÛ¸µº° ºÐ¼®
¼ÒÇÁÆ®¿þ¾î
¼ºñ½º
Á¦7Àå À¯ÀüüÇпë ÀΰøÁö´É ¼¼°è ½ÃÀå ºÐ¼® : ±â¼úº°
±â¼úº° °³¿ä
½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
±â¼úº° ºÐ¼®
±â°èÇнÀ
µö·¯´×
Áöµµ ÇнÀ
°ÈÇнÀ
ºñÁöµµ ÇнÀ
±âŸ ±â°èÇнÀ ±â¼ú
±âŸ ±â¼ú
Á¦8Àå À¯ÀüüÇпë ÀΰøÁö´É ¼¼°è ½ÃÀå ºÐ¼® : ±â´Éº°
±â´Éº° °³¿ä
½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
±â´Éº° ºÐ¼®
°Ô³ð ½ÃÄö½º
À¯ÀüÀÚ ÆíÁý
ÀÓ»ó ¿öÅ©Ç÷οì
¿¹Ãø À¯ÀüÀÚ °Ë»ç·Î ¿¹¹æÀÇÇÐ
Á¦9Àå À¯ÀüüÇпë ÀΰøÁö´É ¼¼°è ½ÃÀå ºÐ¼® : ¿ëµµº°
°³¿ä : ¿ëµµº°
½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
ºÐ¼® : ¿ëµµº°
Áø´Ü
Drug Discovery¡¤ÀǾàǰ °³¹ß
Á¤¹ÐÀÇ·á
³ó¾÷¡¤µ¿¹° ¿¬±¸
±âŸ ¾ÖÇø®ÄÉÀ̼Ç
Á¦10Àå À¯ÀüüÇпë ÀΰøÁö´É ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
ÇコÄɾî ÇÁ·Î¹ÙÀÌ´õ
¿¬±¸ ¼¾ÅÍ, Çмú±â°ü
Á¤ºÎ±â°ü
±âŸ ÃÖÁ¾»ç¿ëÀÚ
Á¦11Àå À¯ÀüüÇпë ÀΰøÁö´É ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°
»óÀ§ ±â¾÷ Á¡À¯À² ºÐ¼®
¼·Ð
ºÏ¹Ì ÆÇ¸Å ºÐ¼®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
ºÏ¹Ì : ºÎ¹®º°
ºÏ¹Ì : ±¹°¡º°
¹Ì±¹
ij³ª´Ù
¸ß½ÃÄÚ
À¯·´ ÆÇ¸Å ºÐ¼®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
À¯·´ : ºÎ¹®º°
À¯·´ : ±¹°¡º°
¿µ±¹
ÇÁ¶û½º
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
Áß±¹
Àεµ
ÀϺ»
Çѱ¹
È£ÁÖ
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
Æä·ç
Ä¥·¹
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
À̽º¶ó¿¤
³²¾ÆÇÁ¸®Ä«°øÈ±¹
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦12Àå À¯ÀüüÇпë ÀΰøÁö´É ±â¾÷ÀÇ °æÀï ±¸µµ
À¯ÀüüÇпë ÀΰøÁö´É ½ÃÀå °æÀï
ÆÄÆ®³Ê½Ê/Á¦ÈÞ/ÇÕÀÇ
ÇÕº´¡¤Àμö
½ÅÁ¦Ç° Ãâ½Ã
±âŸ °³¹ß
Á¦13Àå ±â¾÷ °³¿ä
±â¾÷ Á¡À¯À² ºÐ¼®
½ÃÀå ÁýÁßµµ
IBM(¹Ì±¹)
Microsoft(¹Ì±¹)
NVIDIA Corporation(¹Ì±¹)
Deep Genomics(ij³ª´Ù)
Benevolent ÀΰøÁö´É(¿µ±¹)
Fabric Genomics Inc.(¹Ì±¹)
Verge Genomics(¹Ì±¹)
Freenome Holdings Inc.(¹Ì±¹)
MolecularMatch Inc.(¹Ì±¹)
Cambridge Cancer Genomics(¿µ±¹)
SOPHiA GENETICS(¹Ì±¹)
Data4Cure Inc.(¹Ì±¹)
PrecisionLife Ltd(¿µ±¹)
Genoox Ltd.(¹Ì±¹)
Lifebit(¿µ±¹)
Diploid(º§±â¿¡)
FDNA Inc.(¹Ì±¹)
DNAnexus Inc.(¹Ì±¹)
Empiric Logic(Ireland)
Engine Biosciences Pte. Ltd.(¹Ì±¹)
KSA
The global demand for Artificial Intelligence in Genomics Market is presumed to reach the market size of nearly USD 11.22 BN by 2030 from USD 1.13 BN in 2022 with a CAGR of 33.3% under the study period 2023 - 2030.
Artificial Intelligence in Genomics involves the utilization of machine learning in the field of healthcare to diagnose and understand genetic disorders. AI in genomics helps healthcare professionals to understand better deadly diseases like cancer and several rare and degenerative conditions in patients. AI helps in the structuring of genomic data, and this helps a great deal in interpreting diseases faster than doing it through human intervention. It enables a faster analysis of the structure, functioning and development of the genetic materials.
MARKET DYNAMICS:
Artificial Intelligence in Genomics market shows a satisfactory growth rate during the projection period. The role of genomics in personalized medicine will help the growth of this market as the application of AI helps in the faster manufacturing of medicines. The necessity to reduce time and cost in drug development and increase investments made in AI in genomics by the public and private sector organizations have contributed to the market's growth. Moreover, the growing manufacturing of precision medicine, which focuses on the role of genetics, lifestyle, and environment in the diseases in humans, is another market driver of growth. Similarly, the personalized medicine method that uses patients' genetic profiles to discover the individual patient requirements before prescribing medicine is likely to influence the growth of the AI in genomics market.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of artificial intelligence in genomics. The growth and trends of artificial intelligence in genomics industry provide a holistic approach to this study.
MARKET SEGMENTATION:
This section of the artificial intelligence in genomics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Offering
By Technology
Machine Learning
Deep Learning
Supervised Learning
Reinforcement Learning
Unsupervised Learning
Other Machine Learning Technologies
Other Technologies
By Functionality
Genome Sequencing
Gene Editing
Clinical Workflows
Predictive Genetic Testing & Preventive Medicine
By Application
Diagnostics
Drug Discovery & Development
Precision Medicine
Agriculture & Animal Research
Other Applications
By End User
Pharmaceutical & Biotech Companies
Healthcare Providers
Research Centers, Academic Institutes
Government Organizations
Other End Users
REGIONAL ANALYSIS:
This section covers the regional outlook, which accentuates current and future demand for the Artificial Intelligence in Genomics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the artificial intelligence in genomics market include IBM (US), Microsoft (US), NVIDIA Corporation (US), Deep Genomics (Canada), BenevolentAI (UK), Fabric Genomics Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch Inc. (US), Cambridge Cancer Genomics (UK), SOPHiA GENETICS (US), Data4Cure Inc. (US), PrecisionLife Ltd (UK), Genoox Ltd. (US), Lifebit (UK), Diploid (Belgium), FDNA Inc. (US), DNAnexus Inc. (US), Empiric Logic (Ireland), and Engine Biosciences Pte. Ltd. (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . ARTIFICIAL INTELLIGENCE IN GENOMICS - INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Offering
3.7.2 Market Attractiveness Analysis By Technology
3.7.3 Market Attractiveness Analysis By Functionality
3.7.4 Market Attractiveness Analysis By Application
3.7.5 Market Attractiveness Analysis By End User
3.7.6 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY OFFERING
6.1 Overview by Offering
6.2 Historical and Forecast Data
6.3 Analysis by Offering
6.4 Software Historic and Forecast Sales by Regions
6.5 Services Historic and Forecast Sales by Regions
7 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY TECHNOLOGY
7.1 Overview by Technology
7.2 Historical and Forecast Data
7.3 Analysis by Technology
7.4 Machine Learning Historic and Forecast Sales by Regions
7.5 Deep Learning Historic and Forecast Sales by Regions
7.6 Supervised Learning Historic and Forecast Sales by Regions
7.7 Reinforcement Learning Historic and Forecast Sales by Regions
7.8 Unsupervised Learning Historic and Forecast Sales by Regions
7.9 Other Machine Learning Technologies Historic and Forecast Sales by Regions
7.10. Other Technologies Historic and Forecast Sales by Regions
8 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY FUNCTIONALITY
8.1 Overview by Functionality
8.2 Historical and Forecast Data
8.3 Analysis by Functionality
8.4 Genome Sequencing Historic and Forecast Sales by Regions
8.5 Gene Editing Historic and Forecast Sales by Regions
8.6 Clinical Workflows Historic and Forecast Sales by Regions
8.7 Predictive Genetic Testing & Preventive Medicine Historic and Forecast Sales by Regions
9 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY APPLICATION
9.1 Overview by Application
9.2 Historical and Forecast Data
9.3 Analysis by Application
9.4 Diagnostics Historic and Forecast Sales by Regions
9.5 Drug Discovery & Development Historic and Forecast Sales by Regions
9.6 Precision Medicine Historic and Forecast Sales by Regions
9.7 Agriculture & Animal Research Historic and Forecast Sales by Regions
9.8 Other Applications Historic and Forecast Sales by Regions
10 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY END USER
10.1 Overview by End User
10.2 Historical and Forecast Data
10.3 Analysis by End User
10.4 Pharmaceutical & Biotech Companies Historic and Forecast Sales by Regions
10.5 Healthcare Providers Historic and Forecast Sales by Regions
10.6 Research Centers, Academic Institutes Historic and Forecast Sales by Regions
10.7 Government Organizations Historic and Forecast Sales by Regions
10.8 Other End Users Historic and Forecast Sales by Regions
11 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY GEOGRAPHY
11.1. Top Company Share Analysis
11.2. Introduction
11.3. North America Sales Analysis
11.3.1. Overview, Historic and Forecast Sales Analysis
11.3.2. North America By Segment Sales Analysis
11.3.3. North America By Country Sales Analysis
11.3.4. United State Sales Analysis
11.3.5. Canada Sales Analysis
11.3.6. Mexico Sales Analysis
11.4. Europe Sales Analysis
11.4.1. Overview, Historic and Forecast Sales Analysis
11.4.2. Europe by Segment Sales Analysis
11.4.3. Europe by Country Sales Analysis
11.4.4. United Kingdom Sales Analysis
11.4.5. France Sales Analysis
11.4.6. Germany Sales Analysis
11.4.7. Italy Sales Analysis
11.4.8. Russia Sales Analysis
11.4.9. Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
11.5.1. Overview, Historic and Forecast Sales Analysis
11.5.2. Asia Pacific by Segment Sales Analysis
11.5.3. Asia Pacific by Country Sales Analysis
11.5.4. China Sales Analysis
11.5.5. India Sales Analysis
11.5.6. Japan Sales Analysis
11.5.7. South Korea Sales Analysis
11.5.8. Australia Sales Analysis
11.5.9. Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
11.6.1. Overview, Historic and Forecast Sales Analysis
11.6.2. Latin America by Segment Sales Analysis
11.6.3. Latin America by Country Sales Analysis
11.6.4. Brazil Sales Analysis
11.6.5. Argentina Sales Analysis
11.6.6. Peru Sales Analysis
11.6.7. Chile Sales Analysis
11.6.8. Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
11.7.1. Overview, Historic and Forecast Sales Analysis
11.7.2. Middle East & Africa by Segment Sales Analysis
11.7.3. Middle East & Africa by Country Sales Analysis
11.7.4. Saudi Arabia Sales Analysis
11.7.5. UAE Sales Analysis
11.7.6. Israel Sales Analysis
11.7.7. South Africa Sales Analysis
11.7.8. Rest Of Middle East And Africa Sales Analysis
12 . COMPETITIVE LANDSCAPE OF THE ARTIFICIAL INTELLIGENCE IN GENOMICS COMPANIES
12.1. Artificial Intelligence In Genomics Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments
13 . COMPANY PROFILES OF ARTIFICIAL INTELLIGENCE IN GENOMICS INDUSTRY
13.1. Company Share Analysis
13.2. Market Concentration Rate
13.3. IBM (US)
13.3.1. Company Overview
13.3.2. Company Revenue
13.3.3. Products
13.3.4. Recent Developments
13.4. Microsoft (US)
13.4.1. Company Overview
13.4.2. Company Revenue
13.4.3. Products
13.4.4. Recent Developments
13.5. NVIDIA Corporation (US)
13.5.1. Company Overview
13.5.2. Company Revenue
13.5.3. Products
13.5.4. Recent Developments
13.6. Deep Genomics (Canada)
13.6.1. Company Overview
13.6.2. Company Revenue
13.6.3. Products
13.6.4. Recent Developments
13.7. BenevolentAI (UK)
13.7.1. Company Overview
13.7.2. Company Revenue
13.7.3. Products
13.7.4. Recent Developments
13.8. Fabric Genomics Inc. (US)
13.8.1. Company Overview
13.8.2. Company Revenue
13.8.3. Products
13.8.4. Recent Developments
13.9. Verge Genomics (US)
13.9.1. Company Overview
13.9.2. Company Revenue
13.9.3. Products
13.9.4. Recent Developments
13.10. Freenome Holdings Inc. (US)
13.10.1. Company Overview
13.10.2. Company Revenue
13.10.3. Products
13.10.4. Recent Developments
13.11. MolecularMatch Inc. (US)
13.11.1. Company Overview
13.11.2. Company Revenue
13.11.3. Products
13.11.4. Recent Developments
13.12. Cambridge Cancer Genomics (UK)
13.12.1. Company Overview
13.12.2. Company Revenue
13.12.3. Products
13.12.4. Recent Developments
13.13. SOPHiA GENETICS (US)
13.13.1. Company Overview
13.13.2. Company Revenue
13.13.3. Products
13.13.4. Recent Developments
13.14. Data4Cure Inc. (US)
13.14.1. Company Overview
13.14.2. Company Revenue
13.14.3. Products
13.14.4. Recent Developments
13.15. PrecisionLife Ltd (UK)
13.15.1. Company Overview
13.15.2. Company Revenue
13.15.3. Products
13.15.4. Recent Developments
13.16. Genoox Ltd. (US)
13.16.1. Company Overview
13.16.2. Company Revenue
13.16.3. Products
13.16.4. Recent Developments
13.17. Lifebit (UK)
13.17.1. Company Overview
13.17.2. Company Revenue
13.17.3. Products
13.17.4. Recent Developments
13.18. Diploid (Belgium)
13.18.1. Company Overview
13.18.2. Company Revenue
13.18.3. Products
13.18.4. Recent Developments
13.19. FDNA Inc. (US)
13.19.1. Company Overview
13.19.2. Company Revenue
13.19.3. Products
13.19.4. Recent Developments
13.20. DNAnexus Inc. (US)
13.20.1. Company Overview
13.20.2. Company Revenue
13.20.3. Products
13.20.4. Recent Developments
13.21. Empiric Logic (Ireland)
13.21.1. Company Overview
13.21.2. Company Revenue
13.21.3. Products
13.21.4. Recent Developments
13.22. Engine Biosciences Pte. Ltd. (US)
13.22.1. Company Overview
13.22.2. Company Revenue
13.22.3. Products
13.22.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies